Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: Single-center analysis of eight biomarkers in a series of three hundred six patients

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages 537-544

  Otto, Wolfgang ^a   Denzinger, Stefan ^a   Fritsche, Hans Martin ^a   Burger, Maximilian ^b   Rößler, Wolfgang ^a   Bertz, Simone ^c   May, Matthias ^d   Hartmann, Arndt ^c   Hofstädter, Ferdinand ^a   Wieland, Wolf F ^a   Eder, Fabian ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Urologische Klinik   (Germany)

Author keywords

Biomarkers; Early invasive bladder cancer; Immunohistochemistry; Prognosis; Urothelial bladder carcinoma

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 20; FIBRONECTIN; KI 67 ANTIGEN; MUCIN 7; SURVIVIN; TRANSCRIPTION FACTOR RUNX2; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; VALIDATION PROCESS;

BIOMARKERS; EARLY INVASIVE BLADDER CANCER; IMMUNOHISTOCHEMISTRY; PROGNOSIS; UROTHELIAL BLADDER CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84887998423     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.05.001     Document Type: Article

References (35)

1. E. Langer Immunohistology. Principles, methods and results [Article in German] Med Klin 57 1962 1724 1728
2. W. Dutz, and B. Ernst Technics of immunohistology [Article in German] Z Med Labortech 7 1966 205 225
3. G. Costanzi, U.M. Mancini, and G.A. Zampa Experimental research on insulin antibodies. III. Immunohistology of the endocrine pancreas with guinea pig anti-bovine insulin serum, conjugated with fluorescin isothiocyanate [Article in Italian] Boll Soc Ital Biol Sper 37 1961 1233 1235
4. K. Lange, G. Treser, and I. Sagel Routine immunohistology in renal diseases Ann Intern Med 64 1966 25 40
5. S. von Kleist, E. Chany, and P. Burtin Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor J Natl Cancer Inst 55 1975 555 560
6. D.Y. Mason, and P. Biberfeld Technical aspects of lymphoma immunohistology J Histochem Cytochem 28 1980 731 745
7. W.B. Nathrath, H. Arnholdt, and P.D. Wilson Keratin, luminal epithelial antigen and carcinoembryonic antigen in human urinary bladder carcinomas. An IHC study Pathol Res Pract 175 1982 299 307
8. T.A. Flam, D.K. Chopin, and C. Leleu Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors Eur Urol 17 1990 338 342
9. A.H. Mulder, J.C. Van Hootegem, and R. Sylvester Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67) J Patho 166 1992 37 43
10. K. Matsushita, E.K. Cha, and K. Matsumoto Immunohistochemical biomarkers for bladder cancer prognosis Int J Urol 18 2011 616 629
11. O. Shahin, G.N. Thalmann, and C. Rentsch A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 2003 96 100 discussion 100
12. M. Babjuk, W. Oosterlinck, and R. Sylvester European Association of Urology (EAU) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
13. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of Malignant Tumours 7th ed 2010 Wiley-Blackwell Hoboken: NJ 246 249
14. Tumours of the urinary system L. Eble, G. Sauter, and J.I. Epstein World Health Organization Classification of Tumours - Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004 IARC Press Lyon, France
15. R. Hurle, A. Losa, and A. Manzetti Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up Urology 54 1999 258 263
16. T. Lebret, F. Gaudez, and J.M. Herve Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success Eur Urol 34 1998 67 72
17. A. Orsola, I. Trias, and C.X. Raventós Initial high-grade t1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients Eur Urol 48 2005 231 238
18. S. Denzinger, M. Burger, and H.M. Fritsche Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder Scand J Urol Nephrol 43 2009 282 287
19. B.W. van Rhijn, T.H. van der Kwast, and S.S. Alkhateeb A new and highly prognostic system to discern T1 bladder cancer substage Eur Urol 61 2012 378 384
20. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466-5; discussion 475-7
21. S. Bertz, S. Denzinger, and W. Otto Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series Histopathology 59 2011 722 732
22. M. Brake, H. Loertzer, and R. Horsch Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin J Urol 163 2000 1697 1705
23. V. Pansadoro, P. Emiliozzi, and F. de Paula Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience Urology 59 2002 227 231
24. S. Bertz, W. Otto, and S. Denzinger Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer Eur Urol 2012 May 19 [Epub ahead of print]
25. W. Otto, S. Denzinger, and H.M. Fritsche The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer BJU Int 107 2011 404 408
26. A. Rodríguez Alonso, S. Pita Fernández, and J. González-Carreró Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67 [Article in Spanish] Actas Urol Esp 27 2003 132 141
27. A. Lopez-Beltran, R.J. Luque, and J. Alvarez-Kindelan Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters Am J Clin Pathol 122 2004 444 452
28. J. Park, C. Song, and E. Shin Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol 2011 Jul 20 [Epub ahead of print]
29. W. Yin, N. Chen, and Y. Zhang Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder Mod Pathol 19 2006 1487 1497
30. C. Weiss, F. von Römer, and G. Capalbo Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy Int J Radiat Oncol Biol Phys 74 2009 1455 1460
31. A. Stepan, C. Simionescu, and C. Mǎrgǎritescu P16, c-erbB2 and Ki67 immunoexpression in urothelial carcinomas of the bladder Rom J Morphol Embryol 52 2011 653 658
32. M. Burger, S. Denzinger, and A. Hartmann Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade Br J Cancer 96 2007 1711 1715
33. S.F. Shariat, C. Bolenz, and G. Godoy Predictive value of combined IHC markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol 182 2009 78 84 discussion 84
34. Y.K. Ye, X.C. Bi, and H.C. He CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma Clin Exp Med 10 2010 153 158
35. F. Barbisan, A. Santinelli, and R. Mazzucchelli Strong IHC expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur Cancer 112 2008 636 644